Management of tricuspid valve regurgitation Position statement of the European Society of Cardiology Working Groups of Cardiovascular Surgery and Valvular Heart Disease
2017
Antunes, M. J. | Rodriguez-Palomares, J. | Prendergast, B. | De Bonis, M. | Rosenhek, R. | Al-Attar, N. | Barili, F. | Casselman, F. | Folliguet, T. | Iung, B. | Lancellotti, P. | Muneretto, C. | Obadia, Jean-François | Pierard, L. | Suwalski, P. | Zamorano, P.
Tricuspid regurgitation (TR) is a very frequent manifestation of valvular heart disease. It may be due to the primary involvement of the valve or secondary to pulmonary hypertension or to the left-sided heart valve disease (most commonly rheumatic and involving the mitral valve). The pathophysiology of secondary TR is complex and is intrinsically connected to the anatomy and function of the right ventricle. A systematic multimodality approach to diagnosis and assessment (based not only on the severity of the TR but also on the assessment of annular size, RV function and degree of pulmonary hypertension) is, therefore, essential. Once considered non-important, treatment of secondary TR is currently viewed as an essential concomitant procedure at the time of mitral (and, less frequently, aortic valve) surgery. Although the indications for surgical management of severe TR are now generally accepted (Class I), controversy persists concerning the role of intervention for moderate TR. However, there is a trend for intervention in this setting, especially at the time of surgery for left-sided heart valve disease and/or in patients with significant tricuspid annular dilatation (Class IIa). Currently, surgery remains the best approach for the interventional treatment of TR. Percutaneous tricuspid valve intervention (both repair and replacement) is still in its infancy but may become a reliable option in future, especially for high-risk patients with isolated primary TR or with secondary TR related to advanced left-sided heart valve disease.
显示更多 [+] 显示较少 [-]